

Parkinson's Disease CSG

David J Burn



INSTITUTE
for
AGEING
and
HEALTH

The PD CSG Team



- Andrew Lees (London)
- David Burn (Newcastle)
- Nin Bajaj (Nottingham)
- Roger Barker (Cambridge)
- Yoav Ben-Shlomo (Bristol)
- Carl Clarke (Birmingham)
- Jeremy Dick (Manchester)
- Donald Grosset (Glasgow)
- Geoffrey Hanks (Bristol)
- John Hardy (London)
- John Hindle (Bangor)
- Tom Isaacs (London)
- Peter Moore (Liverpool)
- Huw Morris (Cardiff)
- Mike Samuel (London)
- Richard Walker (North Tyneside)
- Keith Wheatley (Birmingham)
- Paul Worth (Norfolk & Norwich)

Inaugural Conference 20th June 2007

DeNDRoN PD Portfolio (May '07)

- 3 commercial trials, *incl.*
 - Lundbeck-sponsored RCT of memantine in PDD & DLB
- 11 non-commercial trials, *incl.*
 - PD MED, PD GEN, PD SURG
 - PROMS-PD
 - RCT of targeted exercise on falls & function

Early Successes

- Cohesiveness & enthusiasm
- Disseminating information to key groups
 - e.g. BRIT-MODIS
- Expanding & diversification of the portfolio
 - admixture of commercial & non-commercial studies
- Increasing trial recruitment & awareness
 - e.g. PD MED & PD GEN
- Identification & development of ambitious multi-centre studies tackling high priority research areas

PD CSG Research Initiatives-1

- Predictors of outcome & cost-effectiveness of cholinesterase inhibitor treatment in dementia associated with PD
 - cross-CSG involvement (Dementia)
- Early diagnosis of PD in primary care
 - links needed with Primary Care CSG
 - to include role of ancillary investigations (olfactory function, DaTSCAN etc.)

PD CSG Research Initiatives-2

- Research priorities of patients & carers
 - expert patient & PDS involvement
 - evaluation of outcome measures (?)
- RCT of deep brain stimulation of subthalamic nucleus vs. continuous subcutaneous apomorphine for refractory motor fluctuations

Development of the PD CSG: Generic Issues

- Members to act as local & regional oracles
 - support aims & allay fears
- Encourage pharmaceutical approaches to be made via DeNDRoN mechanism
- Clarification of investigator funding per patient
- Balancing the commercial vs. non-commercial portfolio
 - CSG members to act as “antennae” for hot topics
 - champions of internally generated studies

Development of the PD CSG: Disease Specific Issues

- Diversify beyond Parkinson's disease
 - e.g. PSP & MSA
- Overlap / liaison with other CSGs
 - dementia
 - cognitive & psychosis issues
 - ChEI in PDD as a working example
 - primary care
- Greater development of AHP-related studies